IntelGenX
Our business strategy is to apply our proprietary drug delivery technologies to improve existing drug compounds with proven efficacy and.
Launch date
Employees
Market cap
AUD45.1m
Enterprise valuation
AUD69m (Public information from Sep 2024)
Share price
$0.17 IGXT
Montreal Quebec (HQ)
Financials
Estimates*
USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Revenues | 1.7m | <1m | 1.5m | 1.5m | <1m | 1.0m | 30.9m |
% growth | (65 %) | (57 %) | 108 % | (1 %) | (38 %) | 9 % | 2872 % |
EBITDA | (7.9m) | (8.7m) | (5.1m) | (7.0m) | (8.6m) | (8.7m) | - |
% EBITDA margin | (453 %) | (1177 %) | (331 %) | (459 %) | (909 %) | (836 %) | - |
Profit | (9.6m) | (10.7m) | (7.0m) | (9.3m) | (10.7m) | (9.9m) | - |
% profit margin | (554 %) | (1437 %) | (456 %) | (607 %) | (1125 %) | (955 %) | - |
EV / revenue | 27.4x | 68.5x | 20.7x | 36.9x | 44.7x | 35.9x | - |
EV / EBITDA | -6.0x | -5.8x | -6.3x | -8.0x | -4.9x | -4.3x | - |
R&D budget | 4.9m | 3.8m | 2.6m | 2.7m | 3.0m | 3.3m | - |
R&D % of revenue | 280 % | 509 % | 171 % | 177 % | 319 % | 315 % | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | $1.7m | Post IPO Equity | |
N/A | CAD6.8m | Post IPO Debt | |
N/A | $3.2m | Post IPO Equity | |
$2.0m | Post IPO Debt | ||
$3.0m | Post IPO Debt | ||
* | $3.0m | Post IPO Debt | |
* | N/A | $760k | Post IPO Convertible |
* | CAD3.0m | Post IPO Equity | |
Total Funding | - |
Related Content
Recent News about IntelGenX
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.